The cost-effectiveness of lipid lowering for primary cardiovascular prevention in chronic kidney disease: moving beyond statins
We describe the importance of this topic and explain key assumptions necessary for the investigators to arrive at their conclusions.
Source: Kidney International - Category: Urology & Nephrology Authors: Carl P. Walther, Kevin F. Erickson Tags: Commentary Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Chronic Kidney Disease | Dialysis | Heart | Statin Therapy | Urology & Nephrology | Vytorin | Zetia